List of Studies ( Metabolite:Loroxanthin dodecenoate)
Study_id | Analysis_id | Study_title | Source | Species | Disease | Institute | Units(range) |
---|---|---|---|---|---|---|---|
ST000310 | AN000490 | TC and B6 untreated plasma in lupus-prone mice lipidomics (part-II) | Blood | Mouse | Lupus | University of Florida | Peak area |
ST000310 | AN000492 | TC and B6 untreated plasma in lupus-prone mice lipidomics (part-II) | Blood | Mouse | Lupus | University of Florida | Peak height |
ST000421 | AN000666 | ms3076 T1D poor glycemic control and control samples | Blood | Human | Diabetes | Mayo Clinic | Peak intensity |
ST000422 | AN000667 | Type 1 Diabetes good glycemic control and controls samples | Blood | Human | Diabetes | Mayo Clinic | Peak intensity |
ST000422 | AN000669 | Type 1 Diabetes good glycemic control and controls samples | Blood | Human | Diabetes | Mayo Clinic | Peak intensity |
ST000422 | AN000670 | Type 1 Diabetes good glycemic control and controls samples | Blood | Human | Diabetes | Mayo Clinic | Peak intensity |
ST002094 | AN003420 | Commensal intestinal microbiota regulates host luminal proteolytic activity and intestinal barrier integrity through β-glucuronidase activity (Part 1) | Feces | Human | Irritable bowel syndrome | Mayo Clinic | raw intensity |
ST002094 | AN003422 | Commensal intestinal microbiota regulates host luminal proteolytic activity and intestinal barrier integrity through β-glucuronidase activity (Part 1) | Feces | Human | Irritable bowel syndrome | Mayo Clinic | raw intensity |
ST000046 | AN000077 | Identification of altered metabolic pathways in Alzheimer's disease, mild cognitive impairment and cognitively normals using Metabolomics (plasma) | Blood | Human | Alzheimers disease | Mayo Clinic | Raw MS Intensities |
ST000047 | AN000080 | Identification of altered metabolic pathways in Alzheimer's disease, mild cognitive impairment and cognitively normals using Metabolomics (CSF) | Cerebrospinal fluid | Human | Alzheimers disease | Mayo Clinic | Raw MS Intensities |